As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate ...

One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

TORONTO — Health Canada has authorized updated COVID-19 vaccines by Pfizer and BioNTech and by Moderna for use this ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Construction work paused at 235 East 42nd Street, David Werner and Metro Loft’s massive office-to-resi conversion in Midtown ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Pfizer is advancing research and building a comprehensive "toolbox" for Vietnamese patients, combining innovative vaccines, ...